Article Versions Notes

Chapeau D, Koustoulidou S, Handula M, Beekman S, de Ridder C, Stuurman D, de Blois E, Buchatskaya Y, van der Schilden K, de Jong M, et al. [²¹²Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors. Pharmaceuticals. 2023; 16(7):985. https://doi.org/10.3390/ph16070985

Chapeau, Dylan, Sofia Koustoulidou, Maryana Handula, Savanne Beekman, Corrina de Ridder, Debra Stuurman, Erik de Blois, Yulia Buchatskaya, Karlijn van der Schilden, Marion de Jong, and et al. 2023. "[²¹²Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors" Pharmaceuticals 16, no. 7: 985. https://doi.org/10.3390/ph16070985

Chapeau, D., Koustoulidou, S., Handula, M., Beekman, S., de Ridder, C., Stuurman, D., de Blois, E., Buchatskaya, Y., van der Schilden, K., de Jong, M., Konijnenberg, M. W., & Seimbille, Y. (2023). [²¹²Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors. Pharmaceuticals, 16(7), 985. https://doi.org/10.3390/ph16070985